{"id":"NCT00730171","sponsor":"Ironwood Pharmaceuticals, Inc.","briefTitle":"An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","officialTitle":"An Open-label, Long-term Safety Study of Oral Linaclotide Administered to Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2012-03","completion":"2012-03","firstPosted":"2008-08-08","resultsPosted":"2018-02-19","lastUpdate":"2018-02-19"},"enrollment":1743,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Irritable Bowel Syndrome With Constipation","Chronic Constipation"],"interventions":[{"type":"DRUG","name":"Linaclotide","otherNames":["Linzess"]}],"arms":[{"label":"Linaclotide","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).","primaryOutcome":{"measure":"Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)","timeFrame":"From first dose of open-label study drug up to 78 weeks","effectByArm":[{"arm":"CC Safety Population: Total","deltaMin":65,"sd":null},{"arm":"IBS-C Safety Population: Total","deltaMin":389,"sd":null},{"arm":"Overall Safety Population: Total","deltaMin":454,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":116,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":607},"commonTop":["Diarrhoea","Urinary tract infection","Sinusitis","Abdominal pain","Nausea"]}}